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Summary B vitamins have beneficial roles in mental health functional impairments; 
however, research on the role of  B vitamins in depression among HIV-infected persons is 
limited. This study assessed the association between dietary B vitamin intake and depres-
sive symptoms in a cohort of  HIV-infected persons. A cross-sectional survey was conducted 
among 314 HIV-infected persons (180 men and 134 women) aged 18 to 60 y residing in 
the Kathmandu, Nepal. The Beck Depression Inventory-I was used to measure depression, 
with a cutoff  score of  20 or higher. Dietary intake was assessed using two nonconsecu-
tive 24-h dietary recalls. The relationships between B vitamins and depressive symptoms 
were assessed using multiple logistic regression analysis. Twenty-six percent participants 
(men: 23%; women: 29%) were depressed. More than two thirds of  participants’ B vitamins 
intake were below the estimated average requirements (EAR) level. Low intake of  riboflavin 
was associated with an increased risk of  depression in women but not in men. Multivari-
ate OR (95% CI) for depression in the first, second, and third tertiles of  riboflavin in total 
participants were 1 (reference), 0.87 (0.46–1.64), and 0.49 (0.24–0.98), respectively (p for 
trend50.048) and in women were 1 (reference), 0.94 (0.36–2.40), and 0.23 (0.07–0.77), 
respectively (p for trend50.020). No clear associations were seen between other B vitamins 
and depressive symptoms in either sex. Low intake of  riboflavin was independently associ-
ated with an increased risk of  depressive symptoms in all participants and in HIV-infected 
women. Further prospective studies are warranted to confirm the role of  vitamin B vitamins 
in depressive symptoms among HIV-infected persons. 
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B vitamins have beneficial roles in mental health 
functional impairments due to their involvement in 
neurochemical pathways in which they regulate the 
homocysteine cycle and synthesize monoamines in 
the brain (1–9). B vitamins provide various enzymes 
required for the metabolism of  homocysteine. For exam-
ple, methylene tetrahydrofolate reductase and flavin 
mononucleotide (a coenzyme of  riboflavin) and cys-
tathionine-B-synthase and y-cystathionase (pyridoxal 
phosphate-dependent enzymes) are involved in the con-
version of  homocysteine to methionine and cysteine 
(1, 2). Methionine has antidepressant properties and is 
involved in the synthesis of  monoamines in the brain 
(10, 11). Thus, a decreased intake of  B vitamins may 
increase depression due to the accumulation of  homo-
cysteine (4–9) and decreased synthesis of  monoamines 
in the brain (10, 11).
In accordance with these biologic mechanisms, sev-
eral observational (12–16) and clinical trials (17–19) 
have reported a potential benefit of  high B vitamin sta-
tus on decreasing the risk of  depression. In the general 
population, cross-sectional and prospective studies have 
found that low intake of  riboflavin (16), pyridoxine (13), 
cobalamin (15, 20–22), and folate (12, 23, 24) were 
associated with increased risk of  depression. Further-
more, in patients with depression, studies have reported 
low serum or plasma concentrations of  pyridoxine (25, 
26) and folate (14, 27–29) in depressive patients. High 
cobalamin (30) and folate (17–19, 31) status has been 
associated with a better response to antidepressant 
treatment. Clinical studies (32, 33) also reported an 
improved mood disturbance among women with thia-
min, riboflavin, and pyridoxine supplementation. Two 
systematic reviews (34, 35) of  dietary intake and 
depression suggested that diet may have a role in the 
aetiology of  depression; however, there is no strong con-
sistency in the findings across different studies that have 
assessed the association between dietary variables and 
depression.
Although studies have shown the benefit of  B vita-
mins against depression in the general population and 
patients with mental disorders, no published studies 
have examined the relationship between B vitamins 
and depression in HIV-infected persons. B vitamin defi-
ciency is common among HIV-infected persons due to 
malabsorption, diarrhea, impaired storage and altered 
metabolism (36–41). Among them, depression is one 
of  the most common co-morbid conditions (42, 43) 
that is associated with higher mortality from both 
AIDS-related and non-AIDS related causes (44, 45). E-mail: kalpana@nursing.umass.edu
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Studies have shown that serum folate concentrations 
were independently associated with hyperhomocystein-
emia in HIV-infected persons (46, 47). Thus, this study 
aimed to assess the association between B vitamins and 
depressive symptoms in persons infected with HIV while 
accounting for important HIV-related clinical and other 
confounders including anti-retroviral therapy (ART). 
As B vitamins have a potential benefit in mental health, 
this study hypothesized that a low intake of  B vitamins 
is associated with depressive symptoms, and tested this 
hypothesis in a sample of  HIV-infected persons. This 
study adds information on the potential benefit of  B 
vitamins in mental health status among the immune-
deficient population, apart from previous studies that 
focused mainly on socio-demographic, psychological, 
and social risk factors of  depression (48).
METHODS
Study design and setting. The present analysis used 
baseline data of  a longitudinal healthy living study enti-
tled “Positive Living with HIV” (POLH) conducted from 
February to March, 2010. This cross-sectional study 
was conducted among people living with HIV-infection 
in the Kathmandu, Lalitpur, and Bhaktapur districts of  
Kathmandu Valley, Nepal. In Nepal, the prevalence of  
HIV-infection was 0.3% in the general population and it 
was particularly high among risky groups, for example 
injecting drug users (IDUs) (6.3%), female sex workers 
(4.2%), men who have sex with men (3.8%), and male 
labor migrants to India (1.8%), in particular to Mumbai 
(49).
Study participants. The study procedures have been 
reported in detail elsewhere (50–56). In brief, HIV-
infected persons were recruited through the network 
of  five non-government organizations (NGOs) working 
with HIV-infected persons in the Kathmandu Valley. Five 
different NGOs were providing need-based care and sup-
port services to HIV-infected persons in the Kathmandu 
Valley during the study period. These NGOs’ staffs con-
tacted approximately 360 HIV-infected persons either 
through phone calls or in person during their visit to 
the NGO. Of  them, 330 participants made a recruitment 
visit, but eight of  them did not participate in the study. 
All together 322 HIV-positive people, aged between 18 
and 60 y, participated in the study voluntarily with 
their written informed consent. None of  the participants 
reported receiving either vitamin or mineral supplemen-
tation in previous 12 mo. The study protocol conformed 
to the ethical guidelines of  the 1975 Declaration of  
Helsinki and was approved by the Ethics Committee of  
the Nepal Health Research Council, Kathmandu, Nepal; 
National Center for Global Health and Medicine, Japan; 
and Waseda University, Tokyo, Japan. The study proce-
dures were also approved by the Institutional Review 
Board of  the University of  Massachusetts, Amherst, 
USA.
Outcome measure. The Nepali version of  the 21-item 
Beck Depression Inventory (BDI)-I was used to measure 
depressive symptoms experienced over the prior 2 wk 
(57, 58). A four-point Likert scale was used to score each 
item, with a total range between 0 and 62 for the instru-
ment. The Nepali version scale was validated in Nepal 
with clinical DSM-IV diagnoses (59) of  major depressive 
disorder (sensitivity 0.73, specificity 0.91; area under 
the curve 0.92). The symptoms of  20 and higher are 
consistent with moderate to severe depressive symptoms 
according to the validation study (57).
Trained interviewers were used to conduct face-to-
face interviews in a private setting using a structured 
pre-tested Nepali version questionnaire. Each interview 
lasted about 45–60 min. Interviewers informed all par-
ticipants about the study procedures using a prepared 
information sheet prior to conduct a survey. Partici-
pants were requested to sign informed consent forms 
prior to being interviewed. Participants were reassured 
about the confidentiality of  their information.
Dietary assessment. The dietary intake was calcu-
lated from 2 24-h dietary recalls 1 wk apart and on 
different weekdays. Trained persons collected detailed 
information on all food and beverages consumed by 
participants in 24 h. The information on food prepara-
tion methods and recipes used including brand names 
of  food products were collected by showing real food 
samples and pictures of  commonly eaten food. The por-
tion size of  food was measured by using locally available 
standard spoons, glasses, bowls, food models, recording 
recipes, and a diet measurement scale. The daily intake 
of  B vitamins was calculated using Indian food tables 
from the Wfood2 program version 1.0 (60). The intake 
of  B vitamins was adjusted for energy intake using the 
nutrient density method calculated by dividing nutrient 
intake by total energy per 1,000 kilo calories (61) and 
was categorized into tertiles for analysis.
Covariates measure. A variety of  information on 
socio-demographic, life-style, cardiovascular risk fac-
tors, and ART was collected using the instruments from 
previous studies conducted in Nepal (62–65). ART use 
was measured by participants’ current use of  medica-
tion at the time of  the survey along with specified dura-
tion and names of  medication and adherence. The past 
history of  any disease was solicited by the question 
“In the past 12 months, did you suffer from any type 
of  diseases including minor illnesses?” with response 
options of  yes or no. If  the response was yes, the signs 
or symptoms of  disease or disease diagnosis with details 
of  health seeking behavior and treatment of  each dis-
ease were queried. The measurement of  other socio-
demographic and life-style variables has been described 
elsewhere (66, 67).
Physical examination. The body weight of  participant 
was measured in kilograms on a digital scale and the 
height was measured in centimeters by a stadiometer. 
Body mass index (BMI) was calculated as body weight 
in kilograms divided by the square of  body height in 
meters. Blood pressure was measured with the Omron 
Automatic Blood Pressure Monitor after the participants 
had been seated for at least 10 min with their feet on the 
floor and their arms supported at heart level. All anthro-
pometric measurements were repeated to estimate mean 
values for these parameters.
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Statistical analyses. Eight participants who did not 
have information on B vitamin intake were excluded, 
resulting in a final study population of  314 partici-
pants (180 men and 134 women). Student’s t test and 
the chi-square test were used to assess the difference 
in demographic, life-style, anthropometric, B vitamin 
intake, and clinical parameters by depression symp-
toms, for continuous variables and categorical variables, 
respectively.
The relationships between B vitamin intake and 
depressive symptoms were assessed using multivariate 
logistic regression analysis. Odds ratios and 95% confi-
dence intervals (CI) for depressive symptoms were cal-
culated across tertiles of  B vitamin intake. Major socio-
demographic characteristics and other confounding 
factors having previous establishment or plausible asso-
ciations with the dependent variable were included as 
covariates in the analyses. Age (years, continuous), sex 
(men or women), alcohol intake (never or ever), smok-
ing (never or ever), body mass index (kg/m2, continu-
ous), history of  any disease in the past 12 mo includ-
ing minor illnesses (yes or no), CD41 T-cell count (cells/
mL; continuous), and ART (yes or no) were adjusted for 
in the multivariate models. The ordinal numbers 0–2 
assigned to tertile categories of  B vitamin intake were 
used to calculate trend associations. All p values were 
two-sided and p values less than 0.05 were considered 
statistically significant. Analyses were performed with 
SAS statistical software version 9.1 (SAS Institute, Inc., 
Cary, NC).
RESULTS
In total, 26% of  participants had depressive symp-
toms. The prevalence of  depressive symptoms was 
higher in women (29.1%) than in men (23.3%). Table 
1 shows the demographic and clinical characteristics 
and B vitamin intake of  the 314 HIV-infected partici-
pants by sex. Men were more likely to smoke or drink 
and had a lower median CD41 T-cell count than women. 
There were no gender differences in B vitamin intake. 
The energy intake in men was significantly higher than 
that in women. Table 2 shows the correlation coeffi-
cients among B vitamins in HIV-infected participants. 
Overall, B vitamins were correlated among each other 
except between folic acid and cobalamin, and niacin 
and folic acid. There was no significant difference in 
demographic or clinical characteristics of  participants 
by riboflavin intake except for sex and smoking. There 
were more men (84/106) and smokers (67/106) in the 
highest tertile of  riboflavin intake (p,0.05). The mean 
Table 1. Baseline characteristics of  HIV-infected persons.
Male Female p-value1
Subjects (n) 180 134
Age (mean6SD, y) 35.60 (6.93) 32.59 (6.95) 0.0002
Smoking (never, %) 51 (28.33) 115 (85.82) ,0.0001
Alcohol consumption (never, %) 151 (83.89) 125 (93.28) 0.011
Anti-retroviral therapy (yes, %) 119 (66.11) 109 (81.34) 0.002
History of  any disease in past 12 mo (yes, %) 104 (57.78) 94 (70.15) 0.024
Body mass index (mean6SD, kg/m2) 21.49 (2.87) 21.97 (3.08) 0.157
CD41 T-cell count (median, range; cells/mL) 333 (41–962) 360 (15–1551) 0.019
Energy intake (mean6SD, kcal) 1,985.35 (600.67) 1,548.34 (443.28) ,0.0001
Thiamin (median, range; mg/1,000 kcal) 0.36 (0.24–0.79) 0.37 (0.23–0.80) 0.151
Riboflavin (median, range; mg/1,000 kcal) 0.35 (0.17–1.32) 0.34 (0.16–0.80) 0.116
Niacin (median, range; mg/1,000 kcal) 5.48 (2.56–9.94) 5.32 (2.66–9.65) 0.382
Pyridoxine (median, range; mg/1,000 kcal) 0.69 (0.40–1.40) 0.71 (0.37–1.52) 0.793
Folic acid (median, range; mg/1,000 kcal) 83.12 (37.48–257.04) 80.70 (31.75–300.73) 0.745
Cobalamin (median, range; mg/1,000 kcal) 0.56 (0.04–3.38) 0.49 (0.04–3.00) 0.519
Values for B vitamin intake are adjusted for energy intake by using the nutrient density method.
1 p values were based on the Student t test for continuous variables and chi-square test for categorical variables.
Table 2. Correlation coefficients among energy-adjusted B vitamins in HIV-infected participants.
B vitamins Thiamin Riboflavin Niacin Pyridoxine Folic acid Cobalamin
Thiamin1 1.000 0.360* 0.719* 0.703* 0.387* 0.202*
Riboflavin1 0.360* 1.000 0.252* 0.343* 0.401* 0.555*
Niacin1 0.719* 0.252* 1.000 0.715* 0.111** 0.357*
Pyridoxine1 0.703* 0.343* 0.715* 1.000 0.362* 0.343*
Folic acid2 0.387* 0.401* 0.111** 0.362* 1.000 0.041**
Cobalamin2 0.202* 0.555* 0.357* 0.343* 0.041** 1.000
Unit: 1 mg/1,000 kcal, 2 mg/1,000 kcal.
* p,0.001, ** p.0.05.
B Vitamins and Depression 391
energy intake and all B-vitamins were significantly 
higher in the highest tertile of  riboflavin intake than 
that of  the lowest tertile (p,0.05): energy (2183.60 
vs 1367.60 kcal), thiamin (0.83 vs 0.52 mg/1,000 
kcal), riboflavin (0.95 vs 0.40 mg/1,000 kcal), niacin 
(12.40 vs 7.30 mg/1,000 kcal), pyridoxine (1.59 vs 
1.00 mg/1,000 kcal), folic acid (200.60 vs 122.60 
mg/1,000 kcal), and cobalamin (1.84 vs 0.60 mg/ 
1,000 kcal) (data not shown in the table).
This study did not find any statistically significant asso-
ciations between B vitamin intake and the prevalence of  
depressive symptoms in total participants except for the 
intake of  riboflavin (Table 3). The multivariate adjusted 
OR (95% CI) for depressive symptoms was 1 (reference), 
0.87 (0.46–1.64) and 0.49 (0.24–0.98), respectively, 
for successive tertiles of  energy-adjusted riboflavin 
intake (p for trend50.048). Table 4 shows the associa-
tion between tertiles of  B vitamin intake and depres-
sive symptoms among men. No significant association 
was observed between B vitamins intake and depressive 
symptoms in men. But a significant inverse association 
between energy-adjusted riboflavin intake and depres-
sive symptoms was found among women (Table 5). The 
multivariate adjusted OR (95% CI) for depressive symp-
toms in women was 1 (reference), 0.94 (0.36–2.40) and 
0.23 (0.07–0.77), respectively, for successive tertiles of  
energy-adjusted riboflavin intake (p for trend50.020).
DISCUSSION
Among six different B vitamins, only low dietary 
intake of  riboflavin was significantly associated with 
increased risk of  depressive symptoms in HIV-infected 
women. This is the first study that has assessed the 
role of  B vitamins in depressive symptoms among HIV-
infected persons adjusting for important confounding 
variables.
The relationship between dietary riboflavin intake 
and depression has received little attention although the 
protective role of  riboflavin intake in depression is recog-
nized (1, 2). This study adds the beneficial role of  ribo-
flavin against depressive symptoms among the immune-
deficient population with poor nutritional status. This 
finding is supported by previous observational study 
conducted among the general population in a developed 
country (16). For example, in the Osaka Maternal and 
Child Health Study (16), a decreased risk of  postpartum 
depression was observed among Japanese women in the 
third quartile of  riboflavin intake as compared to the 
first. In a study from Calgary (68), riboflavin and other 
B vitamins were significantly correlated with Global 




T1 (Lowest) T2 T3 (Highest)
Thiamin (median, range; mg/1,000 kcal) 0.29 (0.23–0.33) 0.36 (0.33–0.40) 0.46 (0.40–0.80)
 No. with depression 24/104 27/105 30/105
  Univariate model OR (95% CI) 1.00 (reference) 1.15 (0.61–2.17) 1.33 (0.71–2.48) 0.364
  Multivariate model2 OR (95% CI) 1.00 (reference) 1.15 (0.59–2.24) 1.22 (0.64–2.33) 0.545
Riboflavin (median, range; mg/1,000 kcal) 0.26 (0.16–0.30) 0.35 (0.30–0.40) 0.44 (0.40–1.32)
 No. with depression 30/104 29/105 22/105
  Univariate model OR (95% CI) 1.00 (reference) 0.94 (0.51–1.71) 0.65 (0.34–1.23) 0.192
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.87 (0.46–1.64) 0.49 (0.24–0.98) 0.048
Niacin (median, range; mg/1,000 kcal) 4.11 (2.56–4.74) 5.36 (4.74–5.91) 6.89 (5.93–9.94)
 No. with depression 30/104 26/105 25/105
  Univariate model OR (95% CI) 1.00 (reference) 0.81 (0.44–1.49) 0.77 (0.41–1.43) 0.406
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.82 (0.43–1.57) 0.74 (0.39–1.42) 0.373
Pyridoxine (median, range; mg/1,000 kcal) 0.57 (0.37–0.65) 0.69 (0.65–0.75) 0.86 (0.75–1.52)
 No. with depression 27/104 29/105 25/105
  Univariate model OR (95% CI) 1.00 (reference) 1.08 (0.59–2.00) 0.89 (0.47–1.66) 0.721
  Multivariate model2 OR (95% CI) 1.00 (reference) 1.02 (0.54–1.94) 0.75 (0.39–1.46) 0.406
Folic acid (median, range; mg/1,000 kcal) 59 (31–71) 82 (71–99) 129 (99–300)
 No. with depression 25/104 28/105 28/105
  Univariate model OR (95% CI) 1.00 (reference) 1.14 (0.61–2.14) 1.14 (0.61–2.14) 0.664
  Multivariate model2 OR (95% CI) 1.00 (reference) 1.35 (0.70–2.61) 1.08 (0.56–2.09) 0.798
Cobalamin (median, range; mg/1,000 kcal) 0.22 (0.04–0.32) 0.50 (0.32–0.75) 1.16 (0.75–3.38)
 No. with depression 24/88 25/105 28/105
  Univariate model OR (95% CI) 1.00 (reference) 0.83 (0.43–1.59) 0.97 (0.51–1.83) 0.948
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.74 (0.37–1.47) 0.85 (0.43–1.67) 0.671
Values for B-vitamin intake are medians for adjusted energy intake by using the nutrient density method for each tertile.
1 Linear trends across tertiles of  B-vitamin intake were tested using ordinal numbers 0–2 assigned to tertile categories.
2 All multivariate models were adjusted for age (years, continuous), sex (men or women), alcohol intake (never or ever), 
smoking (never or ever), body mass index (kg/m2, continuous), history of  any disease in past 12 mo (yes or no), CD41 T-cell 
count (200 or .200; cells/mL), and anti-retroviral therapy (yes or no).
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Assessment of  Functioning (GAF) scores among 97 
community-based adults with mood disorders. A clinical 
trial among 120 healthy adults with supplementation 
of  10 times the recommended daily dose of  9 vitamins, 
or a placebo, reported an improved mood disturbance 
among women with thiamin, riboflavin, and pyridoxine 
supplementation (32, 33).
The benefit of  riboflavin on mental health may be 
explained by the action of  riboflavin coenzymes in the 
remethylation and trans-sulfuration of  homocyste-
ine, as discussed earlier (1, 2). Jacques et al. (8) in the 
Framingham Study population and Ganji and Kafai (9) 
in the National Health and Nutrition Examination Sur-
vey population reported an inverse relationship between 
riboflavin and homocysteine. Thus, hyperhomocystein-
emia may mediate the relationship between increased 
intake of  riboflavin and the decreased risk of  depression.
This study did not find any significant decreased risk of  
depressive symptoms with increased intake of  thiamin, 
niacin, pyridoxine, cobalamin, or folate in HIV-infected 
persons. The findings are both consistent with (16, 24, 
69–71) and contrary to some previous studies (12–16, 
72–75) that assessed the relationship between thiamin, 
niacin, pyridoxine, cobalamin, or folate and depression 
in the general population living in developed countries. 
These discrepancies may be partly ascribed to differ-
ences in the target population, dietary intake, dietary 
assessment methods, depressive symptoms measure-
ment methods, and confounding variables treatment.
In this study cohort, more than two-thirds of  the par-
ticipants’ intake of  B vitamins was below the estimated 
average requirements (EAR) level (76). The majority 
of  participants’ B vitamin intakes were below the EAR 
level; 86.67% for thiamin (,1.0 mg/d), 90.0% for 
riboflavin (,1.1 mg/d), 65.0% for niacin (,12 mg/d), 
24.44% for pyridoxine (,1.1 mg/d), 78.41% for cobala-
min (,2.0 mg/d), and 97.78% for folate (,320 mg/d) in 
men and 94.03% for thiamin (,0.9 mg/d), 93.28% for 
riboflavin (,0.9 mg/d), 88.06% for niacin (,11 mg/d), 
54.48% for pyridoxine (,1.1 mg/d), 88.52% for cobal-
amin (,2.0 mg/d), and 99.25% for folate (,320 mg/d) 
in women. Even the median intake of  these B vitamins 
for the participants in the highest tertiles was below the 
EAR level. It is very likely that the ranges of  B vitamin 
intake are not sufficient to make an association between 
B vitamins and depression. However, an inverse rela-
tionship between only riboflavin and depressive symp-
toms in this study was significant in all participants 
and in women. The prevalence of  depressive symptoms 
in the highest tertile of  riboflavin (20.95%) was lower 
than that in the highest tertiles of  other B vitamins in 
all participants (thiamin: 28.57%; niacin: 23.80%; pyri-
Table 4. Odds ratios and 95% CIs for depressive symptoms according to dietary B vitamin intake in HIV-infected men.
Dietary B vitamins
p value1
T1 (Lowest) T2 T3 (Highest)
Thiamin (median, range; mg/1,000 kcal) 0.29 (0.24–0.32) 0.36 (0.32–0.39) 0.45 (0.40–0.79)
 No. with depression 15/60 14/60 13/60
  Univariate model OR (95% CI) 1.00 (reference) 0.93 (0.39–2.10) 0.83 (0.35–1.93) 0.666
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.92 (0.37–2.28) 0.84 (0.34–2.05) 0.702
Riboflavin (median, range; mg/1,000 kcal) 0.27 (0.17–0.30) 0.35 (0.30–0.40) 0.49 (0.40–1.32)
 No. with depression 14/60 13/60 15/60
  Univariate model OR (95% CI) 1.00 (reference) 0.90 (0.38–2.14) 1.09 (0.47–2.52) 0.829
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.99 (0.39–2.49) 1.07 (0.42–2.74) 0.875
Niacin (median, range; mg/1,000 kcal) 4.12 (2.56–4.69) 5.48 (4.74–6.09) 6.96 (6.21–9.94)
 No. with depression 18/60 12/60 12/60
  Univariate model OR (95% CI) 1.00 (reference) 0.58 (0.25–1.35) 0.58 (0.25–1.35) 0.197
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.52 (0.21–1.27) 0.52 (0.21–1.28) 0.148
Pyridoxine (median, range; mg/1,000 kcal) 0.57 (0.40–0.64) 0.69 (0.65–0.75) 0.86 (0.75–1.48)
 No. with depression 16/60 14/60 12/60
  Univariate model OR (95% CI) 1.00 (reference) 0.83 (0.36–1.91) 0.68 (0.29–1.61) 0.388
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.79 (0.32–1.94) 0.62 (0.24–1.57) 0.318
Folic acid (median, range; mg/1,000 kcal) 62.42 (37.48–73.01) 83.12 (73.09–93.64) 128.77 (94.77–257.04)
 No. with depression 11/60 17/60 14/60
  Univariate model OR (95% CI) 1.00 (reference) 1.76 (0.74–4.16) 1.35 (0.55–3.28) 0.517
  Multivariate model2 OR (95% CI) 1.00 (reference) 2.52 (0.98–6.50) 1.27 (0.49–3.25) 0.656
Cobalamin (median, range; mg/1,000 kcal) 0.24 (0.04–0.36) 0.56 (0.36–0.83) 1.19 (0.84–63.38)
 No. with depression 15/56 10/60 17/60
  Univariate model OR (95% CI) 1.00 (reference) 0.54 (0.22–1.34) 1.08 (0.47–2.44) 0.819
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.60 (0.22–1.57) 1.11 (0.46–2.68) 0.761
Values for B vitamin intake are adjusted for energy intake by using the nutrient density method for each tertile.
1 Linear trends across tertiles of  B vitamins intake were tested using ordinal numbers 0–2 assigned to tertile categories.
2 All multivariate models were adjusted for age (years, continuous), alcohol intake (never or ever), smoking (never or ever), 
body mass index (kg/m2, continuous), history of  any disease in past 12 mo (yes or no), CD41 T-cell count (200 or .200; 
cells/mL), and anti-retroviral therapy (yes or no).
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doxine: 23.80%; folic acid: 26.66; cobalamin: 26.66%). 
Similarly, the prevalence of  depressive symptoms in 
the highest tertile of  riboflavin (17.70%) was lower 
than that in the highest tertiles of  other B vitamins in 
women (thiamin: 35.55%; niacin: 31.11%; pyridoxine: 
31.11%; folic acid: 31.11; cobalamin: 26.66%). Thus, 
the level of  riboflavin in the highest tertile of  ribofla-
vin was perhaps above the threshold where riboflavin’s 
effects on depression could be seen. Further prospective 
studies are needed to assess the effects of  B vitamins in 
the risk of  depression.
Regarding sources of  B vitamins, significant contribu-
tors to the B vitamin intake in the Nepalese diet are rice 
and cereals (77). The common sources of  B vitamins 
in the Nepalese diet are rice (B1, B2), wheat bread (B1, 
B9), pulse/lentils (B1, B6, B9), navy beans (B1), black-
eyed peas (B9), green peas (B1, B3), mushrooms (B2, 
B3), spinach (B2, B6, B9), broccoli (B9), lettuce (B9), 
dried fruits (B6), bananas (B6), mango (B9), oranges 
(B9), tofu (B12), low-fat dairy products and cheese (B2, 
B12), egg (B2, B12), chicken (B3, B6), liver (B3), red 
meat (B2, B12), tuna fish (B6), and trout (B1) (77). The 
mean daily consumption of  food averaged 4586107 g 
of  cereals, 436697 g of  rice, 1736127 g of  colored 
vegetables, 1016191 g of  milk and dairy products, and 
60686 g of  potatoes (77). These items constituted more 
than three-fourths of  the total food weight, whereas the 
amounts and frequency of  the consumption of  meat 
(19643 g), fish (13632 g) and eggs (2614 g) were 
very low.
The present study had some limitations. First, the 
cross-sectional design of  the study does not rule out the 
possibility of  reverse causality and that depressive symp-
toms may influence B vitamin intake. Second, depres-
sion was measured using the BDI scale in our study. 
Though clinical diagnosis is the gold standard, such an 
approach is not feasible in community-based studies. 
The BDI has been validated in the context of  this study 
and has been widely used in epidemiologic studies (78, 
79). Third, a 24 h recall may not provide good estimates 
of  usual dietary intake because of  within-person varia-
tion. However, this would be less relevant in the pres-
ent study population due to the measurement of  dietary 
recalls twice, 1 wk apart, and to the limited variation 
of  dietary intake, as some studies suggest that dietary 
habits tend to remain stable over time (24, 80). Fourth, 
hypohomocysteinemia may mediate the relationship 
between increased intake of  riboflavin and the decreased 
risk of  depression as studies have reported (8, 9) an 
inverse relationship between riboflavin and homocys-
teine. However, the homocysteine level of  participants 
was not measured in this study. Fifth, the possibility of  
Table 5. Odds ratios and 95% CIs for depressive symptoms according to dietary B vitamin intake in HIV-infected women.
Dietary B vitamins
p value1
T1 (Lowest) T2 T3 (Highest)
Thiamin (median, range; mg/1,000 kcal) 0.30 (0.23–0.34) 0.37 (0.34–0.40) 0.48 (0.41–0.80)
 No. with depression 12/44 11/45 16/45
  Univariate model OR (95% CI) 1.00 (reference) 0.86 (0.33–2.23) 1.47 (0.59–3.60) 0.387
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.88 (0.31–2.44) 1.47 (0.57–3.81) 0.411
Riboflavin (median, range; mg/1,000 kcal) 0.25 (0.16–0.30) 0.34 (0.30–0.39) 0.47 (0.39–0.80)
 No. with depression 15/44 16/45 8/45
  Univariate model OR (95% CI) 1.00 (reference) 1.06 (0.44–2.55) 0.41 (0.15–1.12) 0.091
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.94 (0.36–2.40) 0.23 (0.07–0.77) 0.020
Niacin (median, range; mg/1,000 kcal) 3.97 (2.66–4.74) 5.31 (4.76–5.80) 6.65 (5.82–9.65)
 No. with depression 12/44 13/45 14/45
  Univariate model OR (95% CI) 1.00 (reference) 1.08 (0.43–2.73) 1.20 (0.48–3.00) 0.690
  Multivariate model2 OR (95% CI) 1.00 (reference) 1.31 (0.49–3.48) 1.29 (0.49–3.37) 0.602
Pyridoxine (median, range; mg/1,000 kcal) 0.56 (0.37–0.65) 0.73 (0.65–0.76) 0.86 (0.76–1.52)
 No. with depression 10/44 15/45 14/45
  Univariate model OR (95% CI) 1.00 (reference) 1.70 (0.66–4.34) 1.53 (0.59–3.95) 0.387
  Multivariate model2 OR (95% CI) 1.00 (reference) 1.45 (0.54–3.86) 1.28 (0.48–3.45) 0.635
Folic acid (median, range; mg/1,000 kcal) 58.69 (31.75–68.51) 80.18 (68.56–101.52) 130.68 (101.89–300.73)
 No. with depression 13/44 12/45 14/45
  Univariate model OR (95% CI) 1.00 (reference) 0.86 (0.34–2.18) 1.07 (0.43–2.66) 0.868
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.95 (0.36–2.53) 1.08 (0.41–2.83) 0.864
Cobalamin (median, range; mg/1,000 kcal) 0.13 (0.04–0.27) 0.45 (0.27–0.67) 1.12 (0.68–3.00)
 No. with depression 10/32 13/45 12/45
  Univariate model OR (95% CI) 1.00 (reference) 0.89 (0.33–2.39) 0.80 (0.29–2.16) 0.660
  Multivariate model2 OR (95% CI) 1.00 (reference) 0.80 (0.27–2.36) 0.55 (0.17–1.71) 0.292
Values for B vitamin intake are adjusted for energy intake by using the nutrient density method for each tertile.
1 Linear trends across tertiles of  B vitamins intake were tested using ordinal numbers 0–2 assigned to tertile categories.
2 All multivariate models were adjusted for age (years, continuous), alcohol intake (never or ever), smoking (never or ever), 
body mass index (kg/m2, continuous), history of  any disease in past 12 mo (yes or no), CD41 T-cell count (200 or .200; 
cells/mL), and anti-retroviral therapy (yes or no).
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residual confounding cannot be excluded although we 
adjusted for known factors that could influence both B 
vitamin intake and depressive symptoms. Finally, study 
participants were not selected using a random sampling 
method; thus caution should be taken in generaliz-
ing our study findings to the entire population of  HIV-
infected persons in the country.
In conclusion, the present study suggests that higher 
intake of  riboflavin may be associated with low depres-
sive symptoms in all participants and in HIV-infected 
women even after taking account of  ART and other 
important confounding factors. This finding adds the 
importance of  B vitamins in the mental health status of  
HIV-infected persons. Further prospective studies and/
or clinical trials are needed to confirm the role of  B vita-
mins in depression in HIV-infected persons. 
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